Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial dashes hopes for nicotinamide riboside (NR) in Parkinson's disease. The 52-week NOPARK trial found that the popular NAD+-boosting supplement not only failed to slow early Parkinson's progression but actually led to worse motor and nonmotor scores compared to placebo. Despite raising blood NAD+ levels, the biological boost didn't translate into any clinical benefit.
A widely marketed "longevity" supplement just hit a major roadblock. Nicotinamide riboside (NR), a vitamin B3 derivative that boosts NAD+ levels in the body, failed to slow the progression of early Parkinson's disease (PD) in the phase 3 NOPARK trial — the largest and longest study of its kind. Published in JAMA, the 52-week, double-blind, placebo-controlled trial enrolled 410 adults across 11 centers in Norway.
Not only did NR fail to help — it appeared to trend in the wrong direction. Motor scores increased (worsened) in the NR group while improving slightly in the placebo group, and nonmotor symptoms also deteriorated more in the NR arm. While NR did successfully raise blood NAD+ levels, brain imaging showed no corresponding change in cellular energy metabolism or dopamine transporter activity.
By the Numbers:
Why it matters: These results cast serious doubt on NR as a standalone Parkinson's therapy, at least at this dose and duration. Researchers caution that simply swapping in a different NAD+ precursor is unlikely to yield a meaningfully different outcome, and future NAD-targeting trials will need stronger scientific rationale and rigorous safety monitoring.
